GEM3 is a large, UK-wide study with over 60 centres registered to take part. Mr Awadzi as Principal Investigator for the Darent Valley Hospital led the trial supported by the EPU team, the Trust Research Department and the Hospital Pharmacy. They have successfully recruited as many patients as was envisaged and rank in the top 10 nationally of the number of patients recruited.

The GEM3 trial was designed to test the hypothesis that when combined with single dose Methotexate™ (MTX), Getifinib reduces the need for repeat doses of MTX or the need for surgery. This combination has been shown to be safe with no serious side effects.  Initial, small studies have shown promising results of earlier resolution of ectopic pregnancies in women who took Gefitinib™ (a lung cancer drug) in addition to Methotexate™. 

Tubal ectopic pregnancies occur when the fertlised egg is implanted in the Fallopian tube. Unfortunately, such pregnancies do not result in a live birth.  It is important that this diagnosis is made early as if left untreated, the well being of the woman could be affected and can on occasion result in life-threatening internal haemorrhage. Ectopic pregnancies can have a devastating effect on women and their loved ones. Many women who undergo surgical treatment lose their Fallopian tubes. In the early stages, ectopic pregnancies can be treated conservatively, using medication ( Methotrexate™, MTX) or surgically. There are strict criteria that helps guide women to make an informed choice of which method they prefer.  In general,  women with minimal or no symptoms may be suitable for medical treatment.

The GEM3 research team are very grateful to all the women who have taken part in the trial and in so doing contributed to the advancement of scientific knowledge. The researchers hope the findings of the GEM3 study will benefit countless women in future.

These are quotes from some of the patients who took part in the study.
“Initially I participated in the study for my own benfit. However, I realised over the course of the trial what a massive impact this research could have on future treatments for other patients going through the same experience as me. It gave me comfort knowing that this could lead to a positive change and help other people. I would highly recommend taking part in a research study, without them there can be little progress for treatment options for future people. Going through my condition was a hard process and having the option to treat it differently would be a massive benefit to others. My trial was a  positive experience and my research nurse was caring throughout. “   Charlotte.

“Taking part in the GEM3 study has been a gift. I was looked after so thoroughly before and after the treatment by all in the early pregnancy unit, and I hope this study and my participation will help more women in my position. You are all doing an incredible thing.”  Nicola.
 
Written  by Mr Gabriel Awadzi, GEM3 principal investigator - pictured are staff who made this all possible!